CORTICOTROPIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Corticotropin, and what generic alternatives are available?
Corticotropin is a drug marketed by Organics Lagrange and Watson Labs and is included in two NDAs.
The generic ingredient in CORTICOTROPIN is corticotropin. There are ten drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the corticotropin profile page.
Summary for CORTICOTROPIN
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 19 |
Clinical Trials: | 57 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CORTICOTROPIN at DailyMed |
Recent Clinical Trials for CORTICOTROPIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Yangzhou University | N/A |
Rutgers, The State University of New Jersey | Phase 2 |
University of Michigan | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for CORTICOTROPIN
US Patents and Regulatory Information for CORTICOTROPIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Organics Lagrange | CORTICOTROPIN | corticotropin | INJECTABLE;INJECTION | 010831-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Organics Lagrange | CORTICOTROPIN | corticotropin | INJECTABLE;INJECTION | 010831-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Watson Labs | CORTICOTROPIN | corticotropin | INJECTABLE;INJECTION | 088772-001 | Nov 21, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |